Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
precision oncologymedical
Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.
medtechtechnical
Medtech is the industry that designs and sells medical devices, diagnostic tools and health-related software used by doctors, hospitals and patients to prevent, detect or treat illness. Investors care because these products can drive steady revenue or rapid growth depending on regulatory approval, how widely clinicians and insurers adopt them, and the cost advantages they offer — similar to how a popular new tool can reshape a trade and its market.
digital healthmedical
Digital health involves the use of technology, such as apps, wearable devices, and online platforms, to monitor, manage, and improve people's health and healthcare. For investors, it represents a growing industry that combines healthcare with digital innovation, offering new ways to deliver medical services and track wellness, which can lead to advancements in patient care and potential business opportunities.
FREMONT, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending theBTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
